REFERENCES
- Ramos-Casals M, Perez-Alvarez R, Diaz Lagares C, et al.; The BIOGEAS Study Group. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmune Rev. 2010;9:188–193.
- Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res. 2010; 35: 751–756
- Paiva ES, Macaluso DC, Edwards A, et al. Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis. 2000;59:67–70
- Massara A, Cavazzini L, La Corte R. Sarcoidosis appearing during anti-tumor necrosis factor α therapy: a new “class effect” paradoxical phenomenon. Two case reports and review of the literature. Semin Arthritis Rheum. 2010; 39:313–319
- Daïen CI, Monnier A, Claudepierre P, et al. for the Club Rheumatismes et Inflammation (CRI). Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. Rheumatology. 2009;48:883–886
- Hashkes PJ, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin Exp Rheumatol. 2003;21:645–646
- Sturferlt G, Christensson B, Bynke G, et al. Neurosarcoidosis in a patient with rheumatoid arthritis during treatment with infliximab. J Rheumatol. 2007;34:2313–2314
- Louie GH, Chitkara P, Ward MM. Relapse of sarcoidosis upon treatment with etanercept. Ann Rheum Dis. 2008;67: 896–898
- Suzuki J, Goto H. Uveitis associated with sarcoidosis exacerbated by etanercept. Jpn J Ophthalmol. 2009;53:433–444
- Skoie IM, Wildhagen K, Omdal R. Development of sarcoidosis following etanercept treatment: a report of three cases. Rheumatol Int. 2010 [Epub ahead of print].
- Wakefield D, Zierhut M. Controversy: ocular sarcoidosis. Ocul Immunol Inflamm. 2010;18:5–9
- Imrie FR, Dick A. Biologics in the treatment of uveitis. Curr Opin Ophthalmol. 2007;18:481–486
- Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms of cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept and adalimumab. Arthritis Rheum. 2008;58:1248–1257
- Cope AP, Londei M, Chu NR, et al. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex: reversal in vivo by anti-TNF antibodies in patients with rheumatoid arthritis. J Clin Invest. 1994;94:749–760.
- Cope AP, Liblau RS, Yang XD, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med. 1997;185:1573–1584
- Chen X, Bäumel M, Männel DN, et al. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol. 2007; 179:154–161.
- Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in murine autoimmune ‘lupus’ nephritis. Nature. 1998;331: 356–358
- Gordon C, Ranges GE, Greenspan JS, et al. Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice. Clin Immunol Immunopathol. 1989; 52:421–434.
- Qin HY, Chaturvedi P, Singh B. In vivo apoptosis of diabetogenic T cells in NOD mice by IFN-gamma/TNF-alpha. Int Immunol. 2004;16:1723–1732
- Kim EY, Chi HH, Rajaiah R, et al. Exogenous tumour necrosis factor alpha induces suppression of autoimmune arthritis. Arthritis Res Ther. 2008;10: R38
- Cope AP. Regulation of autoimmunity by proinflammatory cytokines. Curr Opin Immunol. 1998;10:669–676